Search Browse Earnings

Aligos Therapeutics, Inc.

Nasdaq:ALGS

Biological Products, (No Diagnostic Substances)·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Aligos Therapeutics, Inc. — SlamSEC

Revenue

$3.6M

-41.7% YoY

FY 2025

Adj. EBITDA

-$88.1M

-2440.5% margin

FY 2025

Net Income

-$131.2M

-3633.6% margin

FY 2025

EPS (Diluted)

-$20.94

FY 2025

Stock Price

$6.95

+4.4%

2026-03-09

52W Range

$3.76 – $13.69

P/E Ratio

-0.3x

Market Cap

$296.1M

Cash

$37.0M

FY 2025

Total Debt

—

Net Cash

$37.0M

FY 2025

Enterprise Value

$259.1M

Debt / EBITDA

0.4x

FY 2025

EV / EBITDA

-2.9x

Employees

—